| Ytd | 68.63% | |
| 1y | 82.98% |
| Open | 2.63 | Prev Close | 2.60 | Low | 2.52 | High | 2.63 | Mkt Cap | 244.39M |
| Vol | 115.62K | Avg Vol | 335.47K | EPS | 0.38 | P/E | 6.79 | Forward P/E | -13.82 |
| Beta | 2.77 | Short Ratio | 6.42 | Inst. Own | 14.97% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-09 | 50-d Avg | 2.36 | 200-d Avg | 2.15 | 1yr Est | 4.00 |
CGEN News
Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflect
Here is how Compugen (CGEN) and Envoy Medical, Inc. (COCH) have performed compared to their sector s
Compugen has improved and now has a more forgiving runway into 2029. This should carry it through MA
Compugen Ltd. (CGEN) Q2 2026 Earnings Call Transcript
Compugen NASDAQ: CGEN said its second-quarter 2026 progress included continued enrollment in its MAI
Compugen (CGEN) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus E
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which met the analyst consensu
COM701 MAIA-ovarian trial progressing as planned with median progression-free survival data from the
HOLON, Israel, July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-st
HOLON, Israel, July 20, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-s
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer
HOLON, Israel, June 18, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-st
Compugen Ltd. (CGEN) Discusses End-to-End AI-Driven Target Discovery in Immuno-Oncology Transcript
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer
HOLON, Israel, June 11, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-st
HOLON, Israel, June 8, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-sta
Compugen (CGEN) is maintained at a "Buy" rating, driven by advancing clinical programs and upcoming
Compugen Ltd. (CGEN) Q1 2026 Earnings Call Transcript
Compugen NASDAQ: CGEN said it remains on track to report interim progression-free survival data in t
Compugen (CGEN) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimat
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst conse
COM701 MAIA-ovarian trial actively enrolling patients across all clinical sites in the U.S., Israel,
HOLON, Israel, May 12, 2026 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-sta
HOLON, Israel, May 4, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-sta
HOLON, Israel, April 9, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-st
Lake Street analyst Chad Messer initiates coverage on Compugen (NASDAQ:CGEN) with a Buy rating an
Compugen (NASDAQ:CGEN) reported quarterly earnings of $0.60 per share which beat the analyst consens
HC Wainwright & Co. analyst Swayampakula Ramakanth initiates coverage on Compugen (NASDAQ:CGE
Non-dilutive strategic transaction expected to extend cash runway into 2029, to advance Compugen'
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which beat the analyst consens
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pionee
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst conse
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.08) per share which missed the analyst conse
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which missed the analyst conse
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead an